Needham & Company LLC Has Lowered Expectations for Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price

Day One Biopharmaceuticals (NASDAQ:DAWN) had its target price decreased by research analysts at Needham & Company LLC from $18.00 to $17.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 59.62% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. TD Cowen began coverage on Day One Biopharmaceuticals in a report on Tuesday, January 13th. They set a “buy” rating and a $34.00 price objective for the company. Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. JPMorgan Chase & Co. upped their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Piper Sandler lifted their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $26.14.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock opened at $10.65 on Wednesday. The company has a market cap of $1.10 billion, a P/E ratio of -10.34 and a beta of -1.26. Day One Biopharmaceuticals has a one year low of $5.64 and a one year high of $13.20. The business has a fifty day moving average of $10.69 and a two-hundred day moving average of $8.77.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%.The company had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. Sell-side analysts predict that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In other news, insider Michael Vasconcelles sold 2,728 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the completion of the sale, the insider directly owned 4,397 shares in the company, valued at $51,005.20. The trade was a 38.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Lauren Merendino sold 5,814 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $67,442.40. Following the completion of the transaction, the insider directly owned 60,157 shares of the company’s stock, valued at approximately $697,821.20. This represents a 8.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 36,461 shares of company stock worth $422,948 over the last three months. Company insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in DAWN. Vanguard Group Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 6,282,376 shares of the company’s stock worth $58,552,000 after purchasing an additional 101,047 shares during the last quarter. Vestal Point Capital LP boosted its stake in Day One Biopharmaceuticals by 94.4% in the 4th quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock worth $48,464,000 after buying an additional 2,525,000 shares during the last quarter. Deerfield Management Company L.P. grew its holdings in Day One Biopharmaceuticals by 26.4% in the 3rd quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company’s stock valued at $33,173,000 after buying an additional 982,282 shares during the period. State Street Corp grew its holdings in Day One Biopharmaceuticals by 32.4% in the 4th quarter. State Street Corp now owns 4,289,566 shares of the company’s stock valued at $39,979,000 after buying an additional 1,049,122 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of Day One Biopharmaceuticals by 2.0% during the 2nd quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company’s stock valued at $26,635,000 after acquiring an additional 79,255 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Key Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Wedbush raised its price target to $30 and kept an “outperform” rating, signaling strong upside potential from current levels and offering a bullish institutional endorsement. Wedbush PT Raise
• Positive Sentiment: Revenue beat — Q4 revenue came in above consensus (company reported ~$53.7M vs est. ~$49.8M), described as record revenue growth, which supports top‑line momentum and future commercial prospects. Earnings Highlights
• Neutral Sentiment: Analyst roundup pieces summarizing multiple firms’ views are circulating, providing varied takes that can sustain volatility as investors parse differing price targets and ratings. Analyst Roundup
• Neutral Sentiment: Short-interest report shows 0 shares noted for the period (data appears anomalous), so current short-interest metrics provide no clear signal and should be treated cautiously.
• Neutral Sentiment: Earnings materials and full transcripts are available for deeper review (presentation and call transcripts), useful for investors who want management commentary on guidance, commercial rollout and cost trajectory. Earnings Presentation
• Negative Sentiment: EPS missed expectations — Q4 GAAP loss was $0.21 per share vs. the consensus loss of $0.17, highlighting ongoing profitability pressure and contributing to near-term downside risk. EPS Miss Coverage
• Negative Sentiment: Some analysts trimmed price targets (Needham cut to $17; HC Wainwright lowered to $22) even while keeping “buy” ratings — these reductions reduce consensus upside and can weigh on sentiment despite revenue strength. Analyst PT Changes

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.